Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 71 Equity-to-Asset is 0.68 as of Dec. 2025, which is 1% below its 10-year median of 0.69. GuruFocus rates THOXF with a GF Score™ of 71/100 and a GF Value™ of $0.16. The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Bioporto AS ranks better than 63.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bioporto AS's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $9.88 Mil. Bioporto AS's Total Assets for the quarter that ended in Dec. 2025 was $14.61 Mil.
Therefore, Bioporto AS's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.68.
The historical rank and industry rank for Bioporto AS's Equity-to-Asset or its related term are showing as below:
THOXF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57 Med: 0.69 Max: 0.88
Current: 0.68
During the past 13 years, the highest Equity to Asset Ratio of Bioporto AS was 0.88. The lowest was 0.57. And the median was 0.69.
THOXF's Equity-to-Asset is ranked better than 63.51% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs THOXF: 0.68
Bioporto AS (OTCPK:THOXF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bioporto AS Equity-to-Asset Related Terms
Bioporto AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bioporto AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a Equity-to-Asset of 0.68 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bioporto AS and its competitors. This is near median its historical median of 0.69. Over the past decade, Bioporto AS's Equity-to-Asset has ranged from 0.57 to 0.88. According to the industry distribution chart, Bioporto AS ranks #77 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 36.5%.
Is Bioporto AS's Equity-to-Asset too high?
Bioporto AS's current Equity-to-Asset of 0.68 is near median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 0.88. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Bioporto AS's value of 0.68 is 15.3% above this industry median. Based on the distribution chart, Bioporto AS ranks #77 out of 211 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #77 out of 211 companies for Equity-to-Asset. This puts Bioporto AS in the upper half of its industry. The industry median Equity-to-Asset is 0.59. Bioporto AS's value of 0.68 is 15.3% above this benchmark. Historically, Bioporto AS's own Equity-to-Asset has ranged from 0.57 to 0.88 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 0.59, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Equity-to-Asset of 0.68 is 15.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Equity-to-Asset is 0.68, which is near median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Equity-to-Asset of 0.68. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current Equity-to-Asset is 0.68, which is near median its 10-year median of 0.69 and 15.3% above the Medical Diagnostics & Research industry median of 0.59. Bioporto AS's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Equity-to-Asset is 0.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.
Key valuation signals for THOXF:
Equity-to-Asset: 0.68 (near median its 10-year median of 0.69)
GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
Industry Position: 15.3% above the Medical Diagnostics & Research median (#77 of 211)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
71GF Score
Get the complete analysis for THOXF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
